Shares of InspireMD, Inc. (NASDAQ:NSPR) have been given a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.

Brokerages have set a twelve-month consensus price target of $5.00 for the company and are predicting that the company will post ($1.35) earnings per share for the current quarter, according to Zacks. Zacks has also given InspireMD an industry rank of 73 out of 256 based on the ratings given to related companies.

NSPR traded up $0.12 during midday trading on Friday, reaching $3.08. The company’s stock had a trading volume of 4,412 shares, compared to its average volume of 141,648. The firm has a fifty day simple moving average of $2.59. InspireMD has a twelve month low of $1.90 and a twelve month high of $15.35.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular diseases. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions.

Featured Article: 12b-1 Fees

Get a free copy of the Zacks research report on InspireMD (NSPR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter.